ARS Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation for ARS-1, an investigational intranasal epinephrine spray that could provide an easy-to-use, convenient and more reliable treatment for severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.
February 19, 2019
· 3 min read